QuidelOrtho stock (QDEL) has fallen 17.3% over the past six months to $13.31, significantly underperforming the S&P 500's 12.8% gain during the same period. Analysts at StockStory advise investors to avoid the stock, citing fundamental weaknesses that outweigh the lower entry price. The firm argues that the current valuation offers a better risk-reward profile elsewhere, specifically pointing to a top digital advertising platform benefiting from the creator economy.
The primary concern for analysts is QuidelOrtho's inability to generate consistent organic growth. Over the last two years, the company's constant currency revenue, a metric that excludes currency fluctuations to reveal underlying demand, has averaged a 2.8% year-on-year decline. StockStory notes that this underwhelming performance suggests increasing competition or market saturation in the medical diagnostics sector. To reverse this trend, QuidelOrtho may need to lower prices or invest heavily in product improvements, both of which could hinder near-term profitability.
Furthermore, the company's return on invested capital (ROIC) has decreased significantly in recent years. This metric measures operating profit relative to the capital raised through debt and equity. The declining ROIC, combined with already low returns, indicates that profitable growth opportunities for QuidelOrtho are scarce. For long-term investors, the risk of permanent capital loss is a critical factor, distinct from short-term price volatility. StockStory identifies this as a deal-breaker for the current investment thesis.
The balance sheet presents additional red flags. QuidelOrtho burned through $211.2 million in cash over the last year. Its debt load of $3.04 billion far exceeds the $123.4 million in cash held on its balance sheet. Analysts describe indebted loss-making companies as particularly risky because they may be forced to raise capital from a disadvantaged position to continue operations. Such capital raises often result in dilution, which acts as a headwind for shareholder returns. Whether any potential financing would be favorable remains unclear.
Despite these concerns, StockStory characterizes the current valuation as reflecting a "market darling" status where much of the good news is already priced in. The firm maintains a cautious stance until QuidelOrtho demonstrates consistent free cash flow generation or successfully materializes its announced financing plans on its balance sheet. Consequently, StockStory recommends looking toward other opportunities rather than holding QDEL.